Equities research analysts expect that Celsion Co. (NASDAQ:CLSN) will report sales of $130,000.00 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Celsion’s earnings. Celsion also posted sales of $130,000.00 in the same quarter last year. The firm is expected to announce its next earnings report before the market opens on Thursday, August 15th.
According to Zacks, analysts expect that Celsion will report full-year sales of $500,000.00 for the current year. For the next fiscal year, analysts expect that the business will report sales of $500,000.00. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Celsion.
Celsion (NASDAQ:CLSN) last released its earnings results on Wednesday, May 15th. The biotechnology company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.01). The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.13 million. Celsion had a negative net margin of 1,954.60% and a negative return on equity of 65.35%.
Shares of CLSN stock traded down $0.03 on Friday, hitting $1.66. 48,190 shares of the stock traded hands, compared to its average volume of 126,755. The company has a quick ratio of 4.22, a current ratio of 4.22 and a debt-to-equity ratio of 0.51. The company has a market cap of $34.00 million, a P/E ratio of -2.44 and a beta of 1.94. Celsion has a 1-year low of $1.35 and a 1-year high of $3.10. The stock’s fifty day moving average is $1.76.
A hedge fund recently raised its stake in Celsion stock. Vanguard Group Inc. lifted its position in shares of Celsion Co. (NASDAQ:CLSN) by 43.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 704,651 shares of the biotechnology company’s stock after acquiring an additional 211,779 shares during the period. Vanguard Group Inc. owned about 3.44% of Celsion worth $1,282,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 4.67% of the company’s stock.
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
Further Reading: Return on Equity (ROE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.